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Abstract
Pancreatic resection is the only treatment option that can lead to a meaningful prolonged survival in pancreatic cancer and, in
some instances, perhaps a potential chance for cure. With the advent of organ and function preserving procedures, its use in
the treatment of chronic pancreatitis and other less common benign diseases of the pancreas is increasing. Furthermore, over
the past two decades, with technical advances and centralization of care, pancreatic surgery has evolved into a safe procedure
with mortality rates of 55%. However, postoperative morbidity rates are still substantial. This article reviews the more
common procedure-related complications, their prevention and their treatment.
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Introduction
Pancreatic surgery, in particular pancreaticoduode-
nectomy (PD), has been called a ‘formidable’ opera-
tion [1]. It is not only a technical challenge to surgeons,
it is also demanding for patients, and it exerts a
substantial logistical strain on healthcare resources.
Resection of the pancreatic head includes the standard
PD popularized by Whipple, as well as its modifica-
tions such as the pylorus-preserving (PP) PD and the
duodenum-preserving pancreatic head resection
(DPPHR). Distal pancreatectomy is used to resect
lesions in the body and/or tail of the pancreas. Early
series published in the late 1960s reported post-
operative morbidity rates of 60% and mortality rates
approaching 25% [2]. Since that time, significant
advances have been made. Crist et al. observed that,
over a 17-year period, there was a gradual reduction of
mortality from 11% to 2% and of complications from
41% to 36% [3]. More recent series from specialized
surgical centers have reported mortality rates following
PD to be less than 5% [1,4–6]. However, morbidity
rates remain high (30%–60%) [2,4,7]. Whilst the
majority of perioperative complications are not life-
threatening, they can, however, amount to increased
lengths of stay and costs, and for cancer patients, delays
in adjuvant therapy.
Pancreatic cancer is the fourth and fifth leading
cause of cancer-related death in men and women
respectively in the United States [8], as in Europe [9].
Pancreatic cancer is notoriously resistant to non-
surgical forms of oncological treatment such as
radio-, chemo-, and immunotherapy [10–14]. Surgical
resection offers the only chance for cure for pancreatic
cancer [15,16]. PD is also the primary treatment for
resectable periampullary tumors. It has been shown
that curative resection is the single most important
factor determining the outcome in patients with
pancreatic adenocarcinoma [17].
Surgery is also becoming increasingly important in
the treatment of chronic pancreatitis. The main goals
of surgery are the relief of intractable pain and
decompression of adjacent organs [18]. Modifications
to the Whipple procedure to preserve anatomic and
functional structures have led to complete pain relief in
about 75%–82% [19,20]. Long-term pain relief and
excellent long-term survival have also been docu-
mented [21]. In addition, surgical treatment of chronic
pancreatitis using a resectional procedure is associated
with a very low mortality of less than 3%. While
no apparent difference in mortality rates has been
found among standard PD, PPPD and DPPHR, the
duodenal-preserving procedures are associated with
significantly lower morbidity rates, ranging between
9% and 22% [18].
Therefore, despite the risks, pancreatic surgery
continues to be a viable undertaking. With 30-day
mortality rates of 5%, or even less, being commonly
reported today [22], focus has now turned on
attempts to lower the morbidity rates, especially since
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postoperative complications contribute to the overall
mortality [23,24]. Medical complications evoked as a
consequence of surgery include cardiac problems,
cerebrovascular accidents, respiratory distress, renal
dysfunction, pneumonia, pulmonary embolism, hepa-
tic and metabolic dysfunction. Due to improved peri-
operative intensive care, medical complications such as
myocardial, pulmonary and thromboembolic prob-
lems have dramatically decreased [18]. The post-
operative medical complication rate is in the order of
4%–19% [25]. Consequently, efforts to reduce mor-
bidity rates are now tuned to the four most frequent
procedure-related complications [26] following
pancreatic resection, namely pancreatic fistula, de-
layed gastric emptying (DGE), septic complications
in particular intra-abdominal abscess, and abdominal
hemorrhage.
Who should perform pancreatic resection: the
role of caseload
The dramatic decline in mortality after PD represents
the most impressive advance of pancreatic surgery
during the past two decades [18]. Many factors have
contributed to this phenomenon, including better
understanding of pancreatic diseases, careful pre-
operative assessment, advances in diagnostics, better
patient selection and improvements in perioperative
care. The development of a variety of surgical techni-
ques has also allowed a more individualized, disease-
directed approach [27–30]. But perhaps one of the
most critical contributing factors is the concept of
centralization. This stemmed from the recognition of
the association between high patient volumes (case-
loads) and good outcome [31], as demonstrated by
various publications (Table I). The development of
such specialist pancreatic centers has been credited
with the dramatic improvement of the immediate
outcome following pancreatic resectional surgery.
Subsequently, another study found that hospital
volume strongly influenced long-term survival after
PD. This suggests that better patient selection and
differences in quality of care may underlie better
outcomes at such high-volume centers [39]. However,
sporadic publications of excellent results have also
been reported from dedicated centers at community
hospitals and university centers [40–42]. Some of these
centers are not high-volume centers [42]. This chal-
lenged the notion that hospital size is a determining
factor and the theory that ‘practice makes better and
safer’. Birkmeyer et al. [43] investigated the association
between surgeon volume and operative mortality, and
the extent to which the observed effects of hospital
volume can be explained by the experience of the
surgeon. They found that, while for many procedures
the observed associations between hospital volume and
operative mortality are largely mediated by surgeon
volume, this was not the case for pancreatic resection.
For pancreatic surgery, patients at high-volume
hospitals had lower mortality rates than those at low-
volume hospitals, regardless of the surgeon volume.
Many other mechanisms may be at play. High-volume
hospitals have a broader range of specialist and
technology-based services, better-staffed intensive care
units, and other resources that are not available at
smaller centers. In addition, such referral centers tend
to have a higher level of experience in the various
departments involved in the detection and manage-
ment of postoperative complications, such as gastro-
enterology and radiology.
Besides using volume as a marker of quality, post-
operative complications are a valid indicator of quality
of care. Dimick et al. [44] found that pancreatic
resection at high-volume hospitals had a lower risk of
aspiration, pneumonia, pulmonary failure, renal failure
and septicemia. However, interestingly, the rates of
surgical complication were not significantly different
between high-volume hospitals and low-volume
hospitals. This finding again reinforces that while
surgical expertise is necessary, this is not sufficient to
guarantee optimal outcomes after high-risk operations.
Notwithstanding, the overwhelming evidence today
indicates that for high-risk procedures, better
outcomes can be achieved at high-volume centers
Table I. Hospital mortality after pancreaticoduodenectomy–-results of low- and high-volume centers and selected results from
specialized centers
Lead author (state and country) Year
Hospital mortality (%)
High-volume
centers
Low-volume
centers
Liebermann (New York, USA) [32] 1995 2.2 19.0
Gouma (Netherlands) [33] 1997 1 16
Bramhall, Neoptolemos (UK) [34,35] 1995/1997 5.9 28
Gordon (Maryland, USA) [36] 1997 1.8 14.2
(Finland) [37] 1996 4.8 11.0
Birkmeyer (Nationwide, USA) [38] 1999 4.1 16.1
Trede [119] 1985–1990 0
Fernandez-del Castillo [112] 1990–1994 0.4
Yeo [1] 1990–1996 1.4
Bu¨chler [26] 1993–1999 2.1
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where one is more likely to find high-volume surgeons
as well as resources that are better equipped to deliver
the complex perioperative care required by patients
who are undergoing high-risk surgery. The finding that
patients with one or more complications after
pancreatic resection had a mortality of 18% versus
only 5.2% for those without complications [44] further
underscores the importance of initiatives to reduce
morbidity rates. We shall now review the four most
frequent procedure-related complications, and discuss
their prevention and treatment.
Pancreatic leakage
The pancreaticoenteric anastomosis is the Achilles heel
of PD and its modifications. Drainage of the pancreatic
remnant to the gastrointestinal tract remains a crucial
step, but it runs the risk of anastomotic breakdown.
Most leaks may run a benign course, requiring just
maintenance of intraoperatively placed drains [45].
However, if it leads to retroperitoneal sepsis with
abscess formation and/or destruction of the sur-
rounding tissues and blood vessels with the potential
for severe hemorrhage, it is the major cause of post-
operative mortality [46].
The reported incidence of pancreatic leaks varies
widely. This can perhaps be explained by different
definitions and reporting of pancreatic leakage, differ-
ences in the underlying disease, and different surgical
techniques. The Heidelberg and Johns Hopkins units
used a similar definition, namely drainage of 450 ml
of amylase-rich fluid per day from intra-abdominal
drains, on or after the tenth postoperative day.
However, many of these leaks are clinically insignif-
icant [45]. Furthermore, the use of operative site drains
has recently been brought into question. A study by
Conlon et al. [47] failed to show a significant reduction
in surgical morbidity with peritoneal drainage. But
instead, a significantly increased proportion of patients
in the drain group developed intraperitoneal sepsis,
fluid collection or fistula. Consequently, here in
Heidelberg, we have changed our practice towards
the earlier removal of drains, by the second or third
postoperative day. In light of these findings, with
the declining use of peritoneal drains or their earlier
removal, there is perhaps a need to universally adopt a
definition that emphasizes the clinical significance
rather than one just based on amount of drainage fluid
output or its amylase content per se. Furthermore,
peritoneal drain outputs cannot differentiate a true
pancreaticoenteric anastomosis breakdown from
extravasation of pancreatic secretions from the
pancreatic stump, which is usually clinically unim-
portant [48]. A clinical leak occurs when the drainage
of amylase-rich drainage fluid is associated with fever,
leukocytosis, sepsis or the need for percutaneous
drainage of an amylase-rich fluid collection [2] or
confirmation of pancreatic anastomosis breakdown
through fistulogram [49]. Data from level 1 studies
have shown a pancreatic leak rate following PD and its
modifications to be from 0% to 13% [18]. The asso-
ciated mortality of pancreatic leaks has markedly
declined over the past two decades, now ranging
between 0% and 5% [18]. This remarkable feat, when
compared to previously reported rates of 40% [45],
perhaps reflects the advancement in diagnostics and
perioperative management that allows the early and
aggressive management of this complication [50].
In the approach to pancreatic leaks, prevention is
certainly better than cure. Particular risk factors for
breakdown of the pancreatic anastomosis are a soft
parenchymal texture of the pancreatic remnant, the
duct size, the size of the remnant gland, the degree of
pancreatic exocrine function and the anastomotic
technique [46]. A distinct association was found
between the size and the degree of fibrosis of the
remnant gland, and the occurrence of complications
[51,52]. It is logical that a fibrotic remnant will facil-
itate the performance of the pancreaticoenteric
anastomsis, while a soft and friable gland will make it
more difficult. The secretion capacity of the remnant
gland is also a determining factor, as continuous
pancreatic secretion has been hypothesized to hinder
healing of the pancreatic stump [53]. The exocrine
function has an inverse relationship to the degree of
parenchymal fibrosis [54]. Patients with chronic
pancreatitis best exemplify this. It is therefore not
surprising that the results of a review of 2,664
pancreatic resections showed that the pancreatic fistula
rate in chronic pancreatitis was 5%, whilst that for
pancreatic cancer, ampullary cancer and bile duct
cancer are 12%, 15% and 33% respectively [55]. While
nothing can be done about the texture of the paren-
chyma intraoperatively, pharmacological manipulation
of the pancreatic exocrine function is possible.
Role of prophylactic octreotide after
pancreatic resection
Octreotide is the octapeptide analogue of somatostatin
which is a powerful inhibitor of pancreatic exocrine
secretion. A number of randomized prospective trials
have examined the role of prophylactic perioperative
octreotide and its impact on the outcome after
pancreatic surgery (Table II). Four level 1 multi-center
studies from European centers used a similar protocol
with the first doses given preoperatively, followed by
three daily doses of 100 mg for 7 days [51,56–58]. In
contrast, two single-center North American studies in
patients with pancreatic cancer used daily doses of
150 mg or 250 mg given for 5 or 7 days [52,59], while
a multicenter study used vapreotide 0.6 mg twice
daily for 7 days [60]. Each European study showed a
40%–50% decrease in overall morbidity rates, with
two of the four trials reporting a specific reduction in
pancreatic leak rates [57,58]. A meta-analysis that
used these four European trials further concluded that
the use of octreotide was a cost-effective strategy [61].
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All North American studies, however, failed to
demonstrate any benefits. A recent multicenter study
from France showed that the usefulness of octreotide is
somewhere between the conclusions of the European
studies, which advocated its routine use, and those of
the North American trials, which concluded that it was
useless [53]. While octreotide decreased (though not
significantly) the rate of intra-abdominal complica-
tions, its use significantly decreased intra-abdominal
complication rates in certain patient subsets, namely
those whose pancreatic duct was less than 3 mm and
when PD was completed by pancreatojejunostomy
(PJ). In agreement with Li-Ling and Irving [62], who
reviewed this topic recently, while current studies have
shown that prophylactic administration of octreotide
did not uniformly reduce the incidence of pancreatic
leak, overall morbidity or mortality after pancreatic
resection, a subset of patients might benefit from it.
Octreotide use is recommended in high-risk pancreatic
glands (soft consistency with small duct) and in centers
with leak rates greater than 10% [2]. To be effective,
the first dose must be given 1–2 hours preoperatively
followed by 3 doses of 100 mg for 5–7 days [18].
Role of surgical technique following PD
The surgical management of the pancreatic stump
following PD demonstrates how science and art can be
applied in unison. Various surgical techniques to deal
with the pancreatic stump have been described with the
aim of achieving low pancreatic leak rates. With regard
to the pancreaticoenteric reconstruction, creative
techniques like end-to-side PJ, end-to-end (invaginat-
ing/telescoping) PJ, pancreaticogastrostomy (PG) have
been used. In a recent report, using a creative techni-
que called ‘binding PJ’, the authors have reported
impressive results in 150 consecutive patients [63].
Efforts have also targeted the pancreatic duct, and
include ductal occlusion or drainage. Sealing of the
pancreaticoenteric anastomosis using fibrin glue has
also been proposed. With regard to the performance of
pancreatic transection, a group from Japan experi-
mented with ultrasonically activated shears (UAS)
[64]. They found that UAS eliminated bleeding and
pancreatic juice leakage from the branches of the PD,
thereby keeping the cut surface dry, which conse-
quently facilitated the anastomosis.
With such a myriad of techniques and innovations to
choose from, one needs to consider the evidence
behind each of these. Investigators at the Johns
Hopkins Hospital prospectively compared PJ and PG
[65]. The incidence of pancreatic anastomotic leak was
11% for PJ and 12% for PG reconstructions. Another
group compared end-to-end (invaginating/telescop-
ing) anastomosis to the end-to-side (duct-to-mucosa)
anastomosis in a prospective, randomized trial [66].
The end-to-end invaginating technique was associated
with higher pancreatic leak rates. Increasingly, more
reports on the safety of the duct-to-mucosa end-to-side
PJ have been published since [4,26,67–69]. Addition
of a temporary external stent to the pancreatic duct has
been hypothesized to further reduce the leak rate, and
indeed this has been shown in a prospective non-
randomized study where the fistula rate was reduced
from 29% to 7% [70]. Other groups, however, have
not observed similar benefits [23,71,72]. In contrast,
ductal occlusion was shown unequivocally to have
higher fistula rates, in addition to increasing the risk of
pancreatic exocrine and endocrine insufficiency [73].
The role of fibrin glue, whether for temporary ductal
occlusion or sealing of the pancreaticoenteric anasto-
mosis, has been shown to be ineffective in preventing
intra-abdominal complications by three controlled
trials [73–75].
These are but some of the studies that have shed
some light on a largely gray area, and they have given us
some sense of where we might tread safely. However,
most of these technical issues will remain controversial
[46]. As such, for now, the preference of the surgeon
and the technique with which the surgeon feels
comfortable with will prevail.
Treatment of pancreatic leak
The key to the successful management of an
established leak is early recognition. Subsequent
Table II. Outcomes data for prospective randomized controlled trials of prophylactic somatostatin analogues versus placebo for patients
undergoing elective pancreatic resection
Author Year N
Pancreatic fistula (%) Overall morbidity (%) Overall mortality (%)
Placebo Octreotide Placebo Octreotide Placebo Octreotide
Bu¨chler [51] 1992 246 38 18 55 32* 5.8 3.2
Pederzoli [56] 1994 252 19 9 29 16* 3.8 1.6
Montorsi [57] 1995 218 20 9* 36 22* 5.6 8.1
Friess [58] 1995 247 22 10* 30 16* 0.8 1.6
Lowy [59] 1997 110 6 12 25 30 0 2
Yeo [52] 2000 211 11 9 34 40 0 1
Sarr** [50] 2003 275 23 24 26 30 1 0
Suc [53] 2004 230 19 17 37 29 7 12
* p50.05 versus corresponding control group. ** this group used vapreotide instead of octreotide.
102 C.-K. Ho et al.
management algorithm will be dictated by the patient’s
condition. The general consensus is for conservative
management in the absence of peritonitis, sepsis,
hemorrhage or organ failure [4,25,46]. This would
consist of effective control of the leak through some
form of external drainage, intravenous antibiotics,
adequate nutritional support and close monitoring
[45]. Abdominal computed tomography (CT) scans
are mandatory to exclude intra-abdominal fluid
collections or abscess. The value of octreotide in the
treatment of established pancreatic fistula is not clear,
with studies showing conflicting results [76–80]. The
majority of cases (70%–90%) with low-output fistula
can be successfully managed in this manner.
On the other hand, early intervention is indicated if
there is an appreciable major complication that cannot
be managed by other means, such as hemorrhage
or an uncontrollable fistula [45,50,81]. The degree of
destruction and inflammation in the retroperitoneum
will likely determine the surgical strategy as well as
prognosticate its success. Completion pancreatectomy
is said to be able to salvage up to 50% of patients
[50,81]. Other procedures short of completion
pancreatectomy include extensive peripancreatic
drainage with or without continuous irrigation, or
occlusion of the pancreatic duct [45]. Such ‘lesser’
procedures are often insufficient [82].
Intra-abdominal abscess
The incidence of intra-abdominal abscess following
pancreatic resection ranges from 1% to 12% [25],
and is frequently secondary to an anastomotic leak
at the pancreaticoenterostomy, hepaticojejunostomy,
gastrojejunostomy or duodenojejunostomy. These
often manifest as right subhepatic or left subdiaph-
ragmatic collections [46,83]. Whenever an intra-
abdominal collection is suspected, a high-quality
contrast-enhanced CT should be performed. The
preferred method of drainage is by percutaneous
radiologically-guided technique. For as long as the
underlying cause (fistula, leakage) is controlled, such
measures are usually adequate. Surgical exploration
and drainage become necessary should such measures
fail.
Hemorrhage
Postoperative bleeding occurs in 3%–13% of patients
following pancreatic surgery as reported by some
recent series [4,53,84]. The incidence of bleeding
complications appears to be related to the type of
resection. The duodenum-preserving procedures
(Beger and Frey) tend to be associated with a slightly
increased rate of gastrointestinal hemorrhage, ranging
from 5% to 10% [18]. Reactionary hemorrhage (within
the first 24 hours) is often the result of inadequate
hemostasis at the time of surgery, a slipped ligature
or bleeding from an anastomosis. While in the latter
case, management is initially conservative, immediate
reoperation is usually necessary in the former situa-
tions. Stress ulcer can be prevented by prophylactic use
of acid secretion inhibitory agents. In any case, it
usually can be managed medically and/or endoscopi-
cally [85]. Another cause of early postoperative
bleeding is diffuse hemorrhage from the retro-
peritoneal operation field. Because of its widespread
nature, an underlying coagulopathy might be a plau-
sible cause. Coagulation disturbances are frequently
seen in jaundiced patients. This hypothesis is suppor-
ted by a multiple-variant regression analysis which
identified jaundice (bilirubin level 45.8 mg/dl) as a
significant risk factor for postoperative hemorrhage
[86]. Other groups have also observed this association
[85,87]. This calls to question the role of preoperative
biliary drainage (PBD). There are at least two meta-
analyses published on this subject. Sewnath et al. [88]
found that there was no difference in the overall death
rate between patients who had PBD and those who had
surgery without PBD. Instead the overall complication
rate was significantly adversely affected by PBD. The
length of hospital stay was also prolonged. They
concluded that PBD carries no benefit. In the
more recent meta-analysis, Saleh et al. [89] found
no evidence of either a positive or an adverse effect of
preoperative biliary stent placement on the outcome
of surgery in patients with pancreatic cancer. The role
of PBD in patients with biliary obstruction undergoing
PD remains, at best, controversial. Despite this, in
clinical practice in Europe as well as in the United
States, most patients with jaundice who present to
the surgeon would have already received biliary
stenting [84]. Unless the risks of PBD are proven
conclusively through randomized trials, the treatment
policy of the gastroenterologist will probably remain
the same.
In contrast to early hemorrhage, late hemorrhage
(1–3 weeks following surgery) often has a more sinister
underlying cause. It is often secondary to an anasto-
motic leak with consequent erosion of retroperitoneal
vessels [90]. The associated mortality rates ranged
from 15% to 58% [87,91]. Another sinister cause is a
pseudoaneurysm. Diagnostics would include endo-
scopy to exclude an intraluminal source, and contrast-
enhanced CT to look for evidence of a leak. Selective
angiography could be considered if a bleeding source
could not be identified by endoscopy. Bleeding
from the pancreaticojejunostomy is a particularly
challenging problem. Management choice includes
completion pancreatectomy or refashioning of the
anastomosis.
Delayed gastric emptying
With the decline in the incidence of pancreatic leaks,
DGE has emerged as the leading procedure-related
morbidity [1,4]. The reported incidence ranged from
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8% to 45% [18]. This wide range may be due to
different definitions used, as there is still no accepted
general criterion. It has been previously attributed
specifically to pylorus preservation. There are eight
studies (evidence level I and II) comparing PD and
PPPD. While three studies showed no difference, three
favored PPPD, and two showed lower DGE rates after
PD compared to PPPD [26,92–98]. Only duodenum-
preserving procedures compared favorably [26,92,99].
Therefore PD has no clear advantage concerning DGE
when compared to PPPD, whilst for chronic pancrea-
titis with focal disease in the head, duodenum-
preserving procedures probably offer significant
advantages. On the other hand, presence of post-
operative complications other than DGE [92,93,100]
and extended radical surgery significantly increased the
rates of DGE [101,102]. Horstmann et al. showed that
patients without any complications had a DGE rate of
1%. But this climbed to 28% and 43% in the presence
of moderate and severe postoperative complications
[92]. Cameron et al. demonstrated that extended
lymphadenectomy not only did not translate into
longer survival, it significantly increased the rate of
complications including DGE (16% versus 6%) [101].
A mechanical etiology for DGE has also been
proposed, and this relates to the method of recon-
struction of the gastrointestinal continuity, which may
cause transient torsion or angulation of the duodeno-
jejunostomy. One group believed that a retrocolic
reconstruction using a single jejunal limb for all three
anastomoses was responsible for much of their DGE.
Postoperative gastroparesis may lead to temporary
gastric distension, which can then potentially lead to
angulation of the anastomosis because it lies relatively
fixed through its retrocolic position. Additionally, the
close proximity of the duodenojejunostomy to the
pancreaticojejunostomy also predisposes the incidence
of DGE in the event of a small pancreaticojejunostomy
leak or a transient postoperative remnant pancreatitis.
Since adopting an antecolic technique, their incidence
of DGE has dropped from 28% to 12%. Then there are
those who believed that the real culprit is an antecolic
reconstruction [100], predisposing the relatively fixed
stomach to angulation or torsion. By placing the
duodenojejunstomy in the infracolic compartment
through a mesenteric window, and away from the
pancreatic and biliary anastomosis, which lie in the
supracolic compartment, the risk of DGE caused by
local inflammation is reduced.
Whilst DGE mostly resolves spontaneously, it is still
a major source of discomfort to the patients because of
the prolonged gastric decompression, not to mention
prolonged hospital stay and higher healthcare costs.
Yeo et al. [103] have shown that DGE could be
reduced by up to 37% following PD with intravenous
erythromycin, a motilin agonist. But if such measures
still fail, the immediate task is to exclude concomitant
intra-abdominal complications, since DGE may
herald an otherwise undetected pancreaticoenteric or
bilioenteric anastomotic leak. Treatment consists of
nasogastric decompression, attention to nutritional
support, reassurance and watchful waiting.
PD for chronic pancreatitis
There are four types of resection of the head of the
pancreas for focal disease in chronic pancreatitis:
standard PD, PPPD, the Beger procedure, the Frey
procedure and its modifications [104]. With the
exception of total pancreatectomy, the reported
operative mortality of operations for chronic pancrea-
titis is less than 3% [19], but yet able to achieve long-
lasting pain relief in about 75%–80% of those treated
[105]. The early and late morbidity after PD is related
to the reduction in insulin secretion, the occurrence of
early and late dumping complaints, and attacks of
cholangitis [20]. This formed the rationale behind the
use of these organ-preserving pancreatic head resec-
tions, with the major advantage being derived from
conservation of the endocrine capacity, and preserva-
tion of the stomach, duodenum and bile duct.
Certainly, being a lesser procedure, when compared to
PD, postoperative morbidity rates following such local
pancreatic head resection are predicted to be lower. In
a prospective randomized trial by Izbicki et al. [99]
comparing PPPD with the Frey’s procedure, the
postoperative morbidity rates were 53.3% for the
former and 19.4% for the latter. DGE was observed to
occur only in the PPPD group. However, when the
Frey procedure was compared with the Beger proce-
dure in another prospective randomized study [106],
the postoperative morbidity rates were not significantly
different (22% versus 32%). As reported in the seminal
review by Bartoli et al. [55], the risk of pancreatic leak
was the lowest in those with chronic pancreatitis. This
is not surprising as, in most cases, the gland is fibrotic
and there is usually some degree of exocrine insuffi-
ciency. Such factors would enhance the safety of the
pancreatic anastomosis. However, in a recent report by
Bu¨chler et al. [26], the fistula rate was almost similar
between patients with chronic pancreatitis (2.3%) and
patients without pancreatitis (2.0%). We may have
perhaps arrived at an era when technical refinements
and advances in perioperative care can offset the risks
posed by a soft gland.
With regard to the long-term sequelae of the endo-
crine and exocrine functions, studies have shown that,
given time, there was no difference in the incidence of
diabetes between operated patients and non-operated
patients [107]. This suggests that, with regard to
endocrine status, progression of disease has a greater
impact than the surgical intervention. In contrast, two
randomized studies had showed better weight gain and
lower rates of exocrine insufficiency after the Beger
procedure when compared to the standard PD and
PPPD [28,108]. The postoperative exocrine function
was comparable between the Frey procedure and the
Beger procedure [106].
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Morbidity following distal pancreatectomy
Distal pancreatectomy has long been held as a lesser,
and hence safer, procedure when compared to resec-
tion of the pancreatic head. Published complication
rates following distal pancreatectomy had ranged from
22% to 37% [109,110], thus challenging this notion.
The reason behind such morbidity rates may be the
incidence of pancreatic leak, which has been reported
to be as high as 26% in a recent series [111]. Bu¨chler
et al. [4] observed that the pancreatic leak rate was in
fact significantly higher following distal pancrea-
tectomy (5.7%) when compared to pancreatic head
resections (3.2%). Various factors have been impli-
cated as having a bearing on the development of
pancreatic leak. These include method of stump
closure, underlying disease process and concomitant
splenectomy [111].
The conventional method for preventing leakage of
pancreatic juice from the cut surface is ligation of the
main pancreatic duct and additional suturing of the
stump to approximate the anterior and posterior
capsule [112]. With the advent of surgical stapling
devices, a new tool was added to the armamentarium of
techniques for sealing the pancreatic stump, which
includes harmonic scalpel, fibrin glue and prolamine
injection. Stapling has been touted as simple, quick
and secure. However, three groups reported no
difference in pancreatic leak rates when the stump was
stapled or sutured [110,111,113]. Perhaps the trick lies
in the type of staples used. Kajiyama et al. [114]
reported that the use of the Multifire GIA 80 stapler
(US Surgical Corporation, Norwalk, CT, USA) was
associated with a lower leak rate when compared to the
TA-55 staple (Autosuture, Ascot, UK). Consequently,
Takeuchi et al. [115] reported an impressive zero
fistula rate with the use of the Powered Multifire GIA
60. A point to note is that all these reports were
retrospective non-randomized reviews of individual
centers’ experience. As always, properly conducted
prospective randomized controlled trials are needed to
resolve this issue.
Emergency distal pancreatomy, especially for
trauma, has also been identified as a risk factor for
development of complications [111,116]. Complica-
tions in general occurred at a rate of 50% in trauma
patients compared to 11% in elective patients [111].
This might be confounded by the presence of con-
comitant injuries to other organ systems. As for
pancreatic leak, the incidence in trauma patients was
60% compared to 11% for patients who had elective
distal pancreatectomy. It remains unclear if the
leak after distal pancreatectomy for trauma is related
to the method of closure or to additional trauma to
the pancreas. Concomitant splenectomy has not
been shown to influence the pancreatic leak rates
[109,117,118]. Fortunately, most of these fistulae heal
with external drainage and seem to have fewer
propensities to cause further complications. This is
perhaps because the pancreatic secretion is not acti-
vated through contact with intestinal enzymes.
Conclusion
Despite being labeled as a ‘formidable’ task, pancreatic
surgery has evolved into a safe procedure with mor-
tality rates of 55% reported by high-volume centers.
One of the main contributors to this achievement is
the concept of centralization. While the surgeon’s
experience is important, the pooling together of multi-
disciplines in such high-volume centers and dedicated
staff experienced in the diagnosis and management
of complications have no doubt contributed to this
phenomenon. Adjunctive therapeutics like the use of
octreotide and preoperative biliary drainage have yet to
be unequivocally proven to be beneficial. Increasingly,
the duct-to-mucosa pancreaticojejunostomy is recog-
nized to be a safe anastomotic technique. Conse-
quently DGE has now emerged to be the most
common postoperative morbidity. The development of
organ-preserving pancreatectomy has given additional
choices for patients with chronic pancreatitis or benign
pancreatic tumors. Such procedures, like the Beger
procedure and the Frey procedure, combines good
efficacy for pain relief with low surgical morbidity and
mortality. While distal pancreatectomy has low
mortality rates, the incidence of complications and, in
particular, pancreatic leaks are still substantial. Further
studies and research will, no doubt, be focused on
strategies to lower the morbidity rates of pancreatic
surgery.
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